Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and pharmacokinetics study of adalimumab with Halozyme's proprietary ENHANZE technology

Trial Profile

Safety and pharmacokinetics study of adalimumab with Halozyme's proprietary ENHANZE technology

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Hyaluronidase
  • Indications Immunological disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 21 Nov 2016 According to a Halozyme Therapeutics, Inc media release, AbbVie has discontinued a development program using the Halozyme ENHANZE™ platform technology and the tumor necrosis factor alpha (TNF-alpha) target following completion of this study in which the target results were not achieved.
    • 21 Nov 2016 Status changed from recruiting to completed, as per a Halozyme Therapeutics media release.
    • 25 Jan 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top